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Abstract Background Heartburn and other symptoms of
gastro-oesophageal reflux occur in *30 % of survey
respondents in multiple countries worldwide. Heartburn and
acid regurgitation are common complaints in the pharmacy,
where patients frequently seek relief through medication
and advice. The growing number of proton-pump inhibitors
available in the over-the-counter setting provides an effi-
cacious choice to patients experiencing frequent heartburn.
Pharmacists can assist patients in their treatment decisions
whilst inquiring about alarm symptoms that should prompt a
physician referral. Aim of the review Provide pharmacists
with a review of current clinical research and expert
guidelines on use of over-the-counter proton-pump inhibi-
tors. Methods This narrative review was conducted to
identify publications relevant to the following themes:
overview of available treatments for frequent episodes of
heartburn/acid regurgitation; treatment algorithms provid-
ing guidance on when to use over-the-counter proton-pump
inhibitors; and the role of the pharmacist in the use of over-
the-counter proton-pump inhibitors. Results Frequent
symptoms of acid reflux, such as heartburn and acid regur-
gitation, can interfere substantially with daily life activities.
Proton-pump inhibitors are the most efficacious treatment
for frequent reflux symptoms and are recommended as an
appropriate initial treatment in uncomplicated cases. Pro-
ton-pump inhibitors have varying pharmacokinetics and
pharmacodynamics across the class; 20 mg esomeprazole
has higher bioavailability and exposure than over-the-
counter omeprazole, for example. However, differences in
clinical efficacy for symptom relief have not been demon-
strated. The safety and tolerability of proton-pump inhibi-
tors have been well established in clinical trial and post-
marketing settings, and use of a short regimen is associated
with a very low likelihood of missing a more serious con-
dition. Pharmacists can assist patients with accurate self-
diagnosis by asking short, simple questions to characterize
the nature, severity, and frequency of symptoms. Addi-
tionally, pharmacists can inquire about alarm symptoms that
should prompt referral to a physician. Pharmacists should
inform those patients for whom over-the-counter proton-
pump inhibitors are appropriate on their proper use. Con-
clusion Over-the-counter proton-pump inhibitors have a
valuable role in the treatment of frequent heartburn. Phar-
macists have the opportunity to guide patients through
selection of the best treatment option for their symptoms.
Keywords Counselling  Esomeprazole  Gastro-
oesophageal reflux  Omeprazole  Over-the-counter
therapy  Pharmacists  Proton-pump inhibitors
Impacts on practice
• Familiarity with the range of products available to
relieve symptoms of acid reflux, such as heartburn and
acid regurgitation, and the evidence supporting their
use in an over-the-counter setting will facilitate the
pharmacist’s ability to guide appropriate selection and
use of treatment.
• The evidence shows that proton-pump inhibitors at
doses approved for over-the-counter settings can be
used safely and effectively in appropriate patients.
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Introduction
Gastro-oesophageal reflux is a common medical problem
with a broad spectrum of symptoms with varying degrees
of severity and frequency [1–5]. The reflux movement of
gastric contents into the oesophagus can cause a range of
symptoms, from hiccups and burping to pain and physical
discomfort [6]. In some cases, tissue damage can occur,
leading to complications including ulcerating lesions and,
in approximately 5–10 % of reflux cases, metaplasia of the
lower oesophagus (Barrett’s oesophagus) [7, 8]. For most
patients, visits to pharmacists and physicians are prompted
when heartburn and acid regurgitation disrupt daily life [6].
There are an increasing number of options available to
consumers for short-term management of reflux symptoms,
which presents an opportunity for pharmacists to help
guide appropriate selection of medications [6]. Guidelines
such as those issued from the World Gastroenterology
Organisation [9], the National Institute for Health and Care
Excellence [10], and the American College of Gastroen-
terology [11] provide recommendations according to
severity and frequency of symptoms, with changes to diet
or lifestyle suggested for all patients and symptomatic use
of antacids or alginates to provide relief for mild-to-mod-
erate symptoms that occur intermittently. Moderate-to-
severe symptoms with frequent recurrence should be
approached with the intent to improve quality of life whilst
preventing future episodes [7]. Because pharmacists are in
the position to guide such selection, it is important for them
to remain current with available products and the evidence
supporting their use in an over-the-counter (OTC) setting
[12].
Aim of the review
The present review summarizes the clinical presentation of
frequent reflux symptoms and available treatments. As
many patients seek guidance from pharmacists on use of
OTC medications [13], recommendations for identifying
appropriate patients who could benefit from OTC proton-
pump inhibitors (PPIs) and a summary of evidence on the
class are provided. The role of the pharmacist in safe and
appropriate use of OTC PPIs is discussed.
Methods
A narrative review was conducted to identify publications
relevant to the following themes:
• Frequent heartburn/acid regurgitation: overview of the
condition and available treatments
• Treatment algorithm for frequent reflux symptoms:
when to use OTC PPIs
• OTC PPIs: review of the class
• Role of the pharmacist in use of OTC PPIs
Literature searches were conducted using PubMed to
identify English-language publications on the topics listed
above from 1990 through 2014. Key search terms included,
but were not limited to, heartburn; acid regurgitation;
gastro-oesophageal reflux; non-prescription drugs; proton
pump inhibitors; pharmacists; and professional role. Rele-
vant literature was reviewed by the authors; information
determined to be relevant to the selected themes of the
review is summarized below. Additional relevant publica-
tions were identified via cross-referencing from the bibli-
ographies of the selected articles. Primary data are
supplemented with expert guidelines on best practice for
the treatment of gastro-oesophageal reflux across the
spectrum of severity and frequency. There are few phar-
macokinetic and pharmacodynamic data available for OTC
formulations of PPIs; we have presented available data for
omeprazole 20 mg and esomeprazole 20 mg because these
formulations are approved in the greatest number of
countries and are available OTC in the largest markets.
Results
Frequent heartburn and acid regurgitation:
overview of the condition and available treatments
Patients with gastro-oesophageal reflux report a range of
symptoms that disrupt quality of life in terms of sleep,
social functioning, overall activity levels, and work [1, 4, 6,
14, 15]. Reflux of stomach contents can cause burning
sensations in the stomach, throat, oesophagus, and trachea,
as well as pain in the stomach, middle of the chest, and in
the back. Some patients describe regurgitation of food, an
acid taste in the mouth, and halitosis; nausea or bloating;
frequent and severe belching; or erosion of tooth enamel.
Nocturnal symptoms, such as pain or coughing when lying
down, can arouse patients and disturb sleep patterns.
Patients may describe having initially mild reflux-asso-
ciated symptoms (such as hiccups, burping, mild heartburn),
with the severity and frequency of symptoms increasing over
time [6]. As the condition worsens, patients seek healthcare
advice [6]. Reported triggers for consulting medical advice
are symptom severity, interference with daily life, and
questions about the potential for controlling symptoms [6].
A systematic review of population-based studies found
that reflux symptoms were prevalent worldwide: in popu-
lation-based studies mean prevalence rates (for periods up
to 12 months) of at least weekly heartburn and/or acid
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regurgitation (or a physician’s diagnosis of gastro-oe-
sophageal reflux) ranged from 18.1 to 27.8 % in North
America, 8.8–25.9 % in Europe, 2.5–7.8 % in East Asia,
8.7–33.1 % in the Middle East, 11.6 % in Australia and
23.0 % in South America [16]. Frequent reflux is associ-
ated with typical symptoms, with 77 % of patients
reporting heartburn, 63 % reporting acid regurgitation, and
41 % reporting both symptoms [4]. Frequent symptoms are
more disruptive than intermittent episodes, although some
patients delay seeking medical attention because they feel
that the condition is not serious [4].
Symptomatic gastro-oesophageal reflux is treated with
agents that counter the direct effects of the acid reflux on
the oesophageal mucosa and/or medications that target
gastric acid production associated with reflux, with dif-
ferent agents being more appropriate depending on the
varying severity and frequency of episodes [4, 7, 17]. The
initial recommendation for management is diet and life-
style changes, such as weight loss and avoidance of foods
or other substances that may trigger reflux [7, 11]. Antacids
and alginates provide temporary, local relief of reflux
symptoms and are recommended for intermittent symp-
toms of mild-to moderate intensity [7]. Data suggest that
some alginate-containing compounds may be more effec-
tive than traditional antacids in post-prandial acid control
[18]. Histamine receptor antagonists (H2RAs) block one
source of the signalling cascade that induces gastric acid
secretion [19]. H2RAs are administered twice daily, and
over time, patients may develop a tolerance to these agents
[7]. The most efficacious therapeutic class available for
short-term treatment of acid reflux symptoms is PPIs [11,
20], which covalently bind the proton pumps that control
the final step of gastric acid production [19]. The number
of PPIs approved for OTC use is increasing [21, 22], and it
is important for pharmacists to understand their place in
therapy relative to other heartburn remedies. Unlike
options that require multiple daily doses, PPIs are admin-
istered once daily [11] and provide a more complete and
durable resolution of symptoms. In a head-to-head trial
conducted in a general practice setting in France in patients
with moderate heartburn with or without acid regurgitation
occurring more than once weekly, 14-day treatment with an
alginate (Gaviscon; Reckitt Benckiser Healthcare, Massy
Cedex, France; 4 9 10 mL/day) was non-inferior to PPI
treatment (omeprazole 20 mg/day) in time to onset but was
less effective than omeprazole by day 7 in total heartburn-
free days [23].
Treatment algorithm for frequent reflux symptoms:
when to use OTC PPIs
A short interview with a patient with symptoms consistent
with acid reflux can identify the appropriate course of
action: OTC medication or referral to physician for follow-
up care [12]. Asking patients to describe their symptoms,
including the frequency, nature, and severity of episodes,
can confirm the correct course of action [12, 24]. It should
be noted that the severity or frequency of symptoms is not
necessarily a marker of underlying disease [25, 26]. As
with all patients presenting with symptoms suggesting
heartburn or acid regurgitation, follow-up questions should
rule out the presence of alarm symptoms that should
prompt a referral for further medical assessment (Table 1).
Alarm features that could be identified in the pharmacy
based on the patient’s responses include symptoms sug-
gestive of cardiac-type chest pain, difficulty in or painful
swallowing, recurrent bronchial symptoms/cough, hoarse-
ness, signs/symptoms of gastrointestinal bleeding, and
progressive unintentional weight loss [9]. Additionally,
older patients who recently began experiencing reflux
symptoms or patients who have a family history of gas-
trointestinal cancers should be referred to their physician
[12, 24]. Pharmacists also should be aware that certain
medications (e.g., nitrates and calcium antagonists) can
predispose patients to reflux events and potentially pre-
cipitate or exacerbate reflux symptoms [27]. Suspicion of a
drug-related cause of reflux symptoms would be a prompt
for consultation with the prescribing physician.
Professional organizations and health authorities
worldwide have similar guidance for the treatment of
heartburn and other reflux symptoms [7, 10, 11]. Patients
with intermittent reflux symptoms should introduce life-
style and dietary changes and use antacids, alginates, or
low-dose H2RAs on demand for symptom control [7].
Patients with frequent typical reflux symptoms should
receive a course of PPIs to provide relief of symptoms prior
to further diagnostic work-up [7, 11]. Endoscopy is not
recommended for patients with typical symptoms unless
they do not respond to PPI therapy [7, 11].
Because many current guidelines were developed before
widespread OTC availability of PPIs, until recently there
were few resources directed toward pharmacists to provide
guidance. Consensus statements and expert algorithms for
pharmacists are beginning to be developed, however, and
as clinical guidelines are updated, the important role that
pharmacists can and should play in the management of
heartburn and acid regurgitation is becoming more appar-
ent [12, 24].
OTC PPIs: review of the class
Pharmacokinetics and pharmacodynamics
Multiple PPIs are currently available OTC, although the
specific agents in the pharmacy may vary from country to
country (Table 2) [21, 22]. PPIs are prodrugs that are
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converted into active compounds in the acidic environment
of the gastric lumen [19]. The PPIs have distinct pharma-
cokinetic properties. As omeprazole is the most widely
available in the pharmacy setting and esomeprazole is the
most recently switched of the OTC PPIs [21, 22], we will
present the pharmacokinetics of these agents at OTC doses.
The reported exposure (area under the curve [AUC]) of
these compounds after 5 days of administration ranges
from 1.6 to 2.3 lmol h/L for omeprazole 20 mg through
2.8–4.2 lmol h/L for esomeprazole 20 mg [28–30]. The
compound half-lives are similar, whilst the time to maxi-
mum serum concentration (tmax) of omeprazole was longer
than esomeprazole in one study [28–30].
The bioavailability of single doses of omeprazole and
esomeprazole has been reported to be 30–40 and 50 %,
respectively [31–33]. After 5 days’ dosing, AUC was 80 %
higher with esomeprazole 20 mg compared with omepra-
zole 20 mg [28]. A study of the pharmacokinetics of
omeprazole in fed and fasting states demonstrated that
exposure was somewhat lower after a breakfast compared
with fasting conditions; however, this difference was not
statistically significant (P = .2505) [34]. Administration
after breakfast was associated with a longer tmax than whilst
fasting (P = .0001) [34]. In a model of esomeprazole
pharmacokinetics developed from 2 studies, the consis-
tency between the AUC and the maximum concentration
(Cmax) under fed and fasting states suggested that the effect
of esomeprazole on gastric pH is not affected by food [35].
At present, dosing instructions recommend taking
omeprazole in the morning, preferably without food, whilst
esomeprazole may be taken any time with or without food
[32, 33]. However, there is evidence suggesting that PPIs
work best clinically when taken in the morning before
breakfast [36].
Pharmacodynamic assessments of the effects of PPIs on
gastric pH have been performed across multiple doses and
time points [28, 37–39]. In studies of PPIs at OTC doses,
esomeprazole 20 mg provided 11–13 h of gastric acid
control [28, 37–39], with longer acid control (percentage of
time intra-gastric pH [4) than pantoprazole 20 mg
Table 1 Questions to assist in identifying individuals who may benefit from over-the-counter proton-pump inhibitors versus those who should
be referred [9, 12]
Inclusion questions Exclusion questions
Goal: Identify patient who may benefit from over-the-
counter proton-pump inhibitor
Goal: Identify alarm symptoms that should prompt immediate referral
What is the nature of the symptoms you are experiencing?
How frequently are the symptoms occurring?
Have you tried any lifestyle changes or medications that
have made your symptoms better or worse?
When did the symptoms start?
Have you experienced any unintentional weight loss, difficulties in or painful
swallowing, recurrent cough, hoarseness/changes in voice, blood in faeces or
vomit?
Do you have a family history of gastric and/or oesophageal cancer?
Table 2 Over-the-counter proton-pump inhibitor availability by country [21, 22]
Drug Year (region) of first OTC
switch approval
Countries where approved for over-the-counter usea
Esomeprazoleb 2013 (EU) Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Ireland, Italy, Lithuania, Norway, Poland, Portugal, Slovak
Republic, Slovenia, Spain, Sweden, the Netherlands, UK, USA
Lansoprazole 2004 (Sweden) Australia, Finland, New Zealand, Portugal, Sweden, USA
Omeprazole 1999 (Sweden) Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Estonia,
Finland, France, Germany, Hungary, Ireland, Italy, Lithuania, Mexico, New Zealand, Poland,
Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, the Netherlands, UK, USA
Pantoprazolec 2008 (Australia) Argentina, Australia, Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Mexico, New Zealand, Norway,
Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, the Netherlands,
UK
Rabeprazole 2010 (Australia) Australia, UK
a Italicized countries are those where the drug is approved for non-prescription sale in a pharmacy-only category
b Esomeprazole 20 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a Decision
of the European Commission dated 26 August 2013
c Pantoprazole 20 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a Decision
of the European Commission dated 12 June 2009
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(P\ .001 [37]; P\ .0001 [39]), lansoprazole 15 mg
(P = .0001 [38]; P = .026 [39]), and omeprazole 20 mg
(P\ .01) [28].
Drug–drug interactions
Clinically relevant drug–drug interactions with OTC PPIs
are unlikely, but pharmacists should be aware of the
potential issues given the important gatekeeper role they
serve to prevent such situations. These interactions are well
characterized in the product labelling [32, 33, 40, 41], but
are summarized here for completeness.
Because PPIs are metabolized by hepatic cytochrome
P450 (CYP) enzymes (CYP2C19 and CYP3A4), exposure
may be influenced by inhibitors and inducers of these
enzymes, and concomitant use with substrates of these
enzymes could cause interactions. Studies have shown
decreased exposure to clopidogrel, which is metabolized to
its active metabolite via CYP2C19, when co-administered
with PPIs including omeprazole and esomeprazole [32, 40].
Although the clinical relevance of this interaction is
uncertain, concomitant use is discouraged as a precaution.
PPIs decrease serum levels of the protease inhibitor ata-
zanavir when used concomitantly, an interaction likely due
to altered absorption from increased gastric pH; the com-
bination is contraindicated with pantoprazole and not rec-
ommended with omeprazole and esomeprazole [32, 40,
41]. PPIs have the potential to alter the absorption of other
drugs with gastric pH-dependent bioavailability (e.g.,
digoxin, ketoconazole) [32, 40, 41], and methotrexate
levels have been reported to increase when given with PPIs
[32, 41]. There have been a few isolated post-marketing
cases in which PPIs resulted in changes to the international
normalized ratio in patients taking anticoagulants (e.g.,
warfarin) [32, 41]. Although these interactions are well
documented, they are unlikely to be clinically important for
the majority of patients using OTC PPIs for a 14-day
course.
Review of clinical data
The efficacy of OTC PPIs after short-term (14-day) regi-
mens has been evaluated in clinical trials [42–46]. Due to
differences in subject populations and study designs, these
efficacy data cannot be directly compared. In parallel
studies with each agent, over a 14-day treatment period, a
regimen of PPIs at OTC doses was associated with similar
improvements from baseline in the percentage of 24-hour
heartburn-free days among subjects with frequent heart-
burn [42, 45, 46]. Nocturnal heartburn can be particularly
problematic and has been shown to disrupt sleep patterns
and impair overall quality of life [47]. A short course
(14 days) of treatment with OTC PPIs has been shown to
increase heartburn-free nights in subjects with frequent
reflux symptoms at baseline [42, 45, 46]. A re-analysis of
14-day outcomes [48] from 2 previously published 4-week
studies [49, 50] with esomeprazole 20 mg in individuals
with frequent night-time heartburn and associated sleep
disturbances demonstrated rapid resolution of heartburn
episodes and sleep disturbances related to reflux symptoms.
Short-term courses of PPI therapy are well tolerated [12,
51–53]. Most adverse events in studies of 14-day treatment
with OTC PPIs were mild and similar to placebo. The most
commonly reported adverse events included headache
(PPI: 1–3 % vs. placebo:\1–3 %) and mild gastrointesti-
nal complaints such as diarrhoea (PPI:\1–3 % vs. placebo:
\1–2 %), abdominal pain (PPI: \1–2 % vs. placebo:
1–2 %), and nausea (PPI:\1–2 % vs. placebo: 1 %) [42,
45, 46]. Rare occurrences of changes in laboratory values
(such as elevated liver enzymes, low sodium or magnesium
levels, and changes in white blood cell counts) have been
reported in the overall clinical trial programs and post-
marketing reports for PPIs [32, 40, 41, 53–55], although
these changes have not been observed in 14-day studies
with OTC PPIs [42, 45, 46].
With proper patient selection (including inclusion for
frequent symptoms and exclusion for alarm symptoms),
short-term use of PPIs has a low likelihood of masking a
more serious condition or causing additional damage to the
oesophagus [12, 56–59]. If a short course of PPIs is not
effective, patients should then consult with a medical
practitioner. Repeated courses of OTC PPIs (more than
approximately 4 per year) should also prompt consultation.
A study performed in the United States to evaluate
whether patients could self-diagnose for a frequent heart-
burn condition and follow use instructions, including the
recommendation for seeking physician care if symptoms
did not resolve, provided reassuring results [60]. Most
study participants accurately self-diagnosed and were
compliant with all instructions. Overall, 75 % of study
participants consulted their physician about heartburn prior
to, during, or after the study. Further, the instructions for
use stated that a physician should be consulted if[14 doses
were taken during the course of the study; a substantial
proportion of participants (86 %) who took [14 doses
consulted with a physician during the study [60].
These findings complement the long history of OTC use
for anti-secretory drugs for heartburn treatment. Antacids
and H2RAs have been available in pharmacies for decades
[61]. At the time that H2RAs were under consideration for
OTC availability, a decision analysis of patient behaviour
and treatment efficacy concluded that OTC H2RAs would
provide symptomatic relief to patients whilst not leading to
an unsafe delay in seeking treatment for gastric cancer
[61]. Present instructions for OTC PPIs limit use for short-
term treatment of reflux symptoms to 14–28 days without
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consulting a physician [32, 40, 41, 55]. Patients should
consult their physician if reflux symptoms recur immedi-
ately after a course of OTC PPIs [32, 40, 41, 55]. If
symptoms recur after 4 months, a subsequent course of
OTC PPIs can be initiated [9].
Role of the pharmacist in the use of OTC PPIs
PPIs are widely acknowledged to be the most effective
treatment for symptom relief of gastro-oesophageal reflux
[11, 24]. Compared with other options, OTC PPIs have
demonstrated benefits to symptom resolution and quality of
life [24] and the practical advantage of more convenient
once-daily dosing [11]. As more formerly prescription
medications enter the OTC market, the role of the phar-
macist in heartburn therapy has expanded, prompting the
development of specific guidance for pharmacists [12, 24].
With their extensive knowledge of OTC drugs and their
familiarity with their patients, pharmacists are ideally sit-
uated to assist in the selection of appropriate medication
[12]. By asking the correct questions (Table 1) as outlined
previously, pharmacists can confirm the presence of fre-
quent reflux and perform an important surveillance func-
tion by identifying patients with alarm symptoms who
should be referred to a physician [12]. These questions
complement the available algorithms developed by expert
gastroenterologists [12, 24]; however, adherence to a par-
ticular structure is not necessary.
Notably, these suggested questions are ones that should
be posed to patients with any severity of symptoms,
including those with intermittent symptoms that might be
adequately addressed with antacids and alginates [7, 11]. It
is important to remember that there is no correlation
between frequency or intensity of the symptoms and the
underlying severity of the condition [25].
Upon confirming the presence of reflux symptoms,
pharmacists should review instructions with the patient to
ensure the proper use of OTC PPIs. Patients should also be
reminded that, unlike antacids, PPIs are not to be taken
symptomatically [32]. Although the patients may feel
better after a few days into the regimen, the mechanism of
OTC PPIs is distinct from antacids, and consequently, the
agents should be administered to their best advantage:
antacids and alginates for local treatment of reflux symp-
toms; PPIs and H2RAs for the inhibition of gastric acid
secretion [7, 19]. PPIs are administered once daily [32, 40,
41, 55]; treatment should be taken at the same time every
day [40, 41, 55]. Currently available OTC PPIs are indi-
cated for short-term regimens of 14–28 days [32, 40, 41,
55]. Although some patients take PPIs for months or years
[62], a long-term treatment regimen should be monitored
by a physician [32, 40, 41, 55].
The pharmacist should set the expectations of treatment
with OTC PPIs. Patients may seek complete resolution of
symptoms yet also anticipate immediate relief of symptoms
[24]. Based on a meta-analysis of 18 studies with agents at
different doses, approximately one-third of patients will
experience relief of heartburn symptoms within a few days
of starting a PPI regimen [24, 63], and approximately
55–80 % of patients experience first resolution/relief of
heartburn symptoms within the first week of treatment,
according to clinical trial data [32, 41]. Pharmacists should
advise that lifestyle changes, including avoiding known
triggers, are complementary to pharmaceutical treatments
for gastro-oesophageal reflux and may increase the likeli-
hood of treatment success [7, 11].
Conclusion
Frequent reflux symptoms are not optimally managed with
antacids or alginates [7, 11]. Guidelines consistently rec-
ommend a short-term course of PPIs for symptom relief in
patients without alarm symptoms [7, 11]. Convenient, easy
to use, and safe, OTC PPIs provide additional value to
pharmacy patients with frequent reflux symptoms [7, 12].
Pharmacists are in the position to guide the selection of the
best treatment by confirming the diagnosis, referring
patients with alarm symptoms to physicians, and educating
patients on the proper use of their OTC medication.
Managing OTC PPI use in the pharmacy is a necessary and
appropriate role for pharmacists.
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